Clinical Nurse Specialist Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Robin Taul

Clinical Nurse Specialist, Psychiatric/Mental Health, Geropsychiatric Cincinnati, OH Clinical Nurse Specialist

NPI 1508631029 CMS profile 11535384

2215 Burnet Ave, Cincinnati, OH 45219

Open in the dashboard

General payments

$1,433

65 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robin Taul of Cincinnati, OH is reported in the CMS Open Payments database as having received $1,433 across 65 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $846 32
2024 General $509 32
2023 General $78 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robin Taul
  • Ohio median
  • Middle half of Ohio
  • National median

In program year 2025, general payments to Robin Taul were reported at $846. Among 40,289 Ohio profiles paid that year, the median was $159 and the middle half received between $47 and $569.

Show as a table
Year Robin Taul Ohio median Middle half National median
2019 $0 $166 $50–$652 $163
2020 $0 $110 $33–$367 $114
2021 $0 $125 $35–$432 $132
2022 $0 $141 $41–$498 $149
2023 $78 $150 $43–$522 $160
2024 $509 $153 $45–$543 $164
2025 $846 $159 $47–$569 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AbbVie, Inc. $493 26 payments
  2. Otsuka America Pharmaceutical, Inc. $241 9 payments
  3. Neurocrine Biosciences, Inc. $192 8 payments
  4. Teva Pharmaceuticals USA, Inc. $165 7 payments
  5. Lundbeck LLC $91 4 payments
  6. Alkermes, Inc. $70 3 payments
  7. Janssen Pharmaceuticals, Inc $61 2 payments
  8. Tris Pharma Inc $47 2 payments
  9. ITI, Inc. $41 2 payments
  10. Noven Therapeutics, LLC $19 1 payment
  11. Other $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $1,433 65 payments
Products named General payments · program years 2023–2025
  1. VRAYLAR Neuroscience $343 23 payments
  2. ABILIFY MAINTENA $240 6 payments
  3. INGREZZA $192 8 payments
  4. ABILIFY ASIMTUFII $152 3 payments
  5. VRAYLAR Neuroscience $150 3 payments
  6. UZEDY $90 4 payments
  7. REXULTI $89 6 payments
  8. Austedo XR $75 3 payments
  9. LYBALVI $70 3 payments
  10. ARISTADA $70 3 payments
  11. Other $475 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

163

Median for Nurse Practitioner: 389

Drug cost

$24,592

Median for Nurse Practitioner: $21,885

Branded share of claims

9.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 16 $23,625
Hydroxyzine Pamoate Generic 20 $340
Duloxetine Hcl Generic 22 $293
Gabapentin Generic 11 $126
Buspirone Hcl Generic 13 $46
Alprazolam Generic 33 $43
Trazodone Hcl Generic 13 $42
Escitalopram Oxalate Generic 12 $27
Lamotrigine Generic 12 $25
Propranolol Hcl Generic 11 $25

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $265
$265 16 —
ABILIFY MAINTENA
  • Lundbeck LLC $46
  • Otsuka America Pharmaceutical, Inc. $24
$71 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $24
  • Lundbeck LLC $24
$48 — —
Dyanavel XR
  • Tris Pharma Inc $47
$47 — —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

65 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Psychiatric/Mental Health, Geropsychiatric in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record